LENZ Therapeutics, Inc. Stock OTC Markets
Equities
GRPH
US52635N1037
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 20.46M | Capitalization | 405M |
---|---|---|---|---|---|
Net income 2024 * | -55M | Net income 2025 * | -70M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 19.8 x |
P/E ratio 2024 * |
-7.25
x | P/E ratio 2025 * |
-6.52
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.31% |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +2.35% | - |
1st Jan change | Capi. | |
---|---|---|
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.69% | 22.2B | |
-16.53% | 21.23B | |
-9.14% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |